A Phase 2 randomized clinical trial published in the prestigious JAMA found that a single dose of psilocybin (accompanied by psychotherapy) resulted in a rapid, robust and sustained reduction in depressive symptoms for people with major depressive disorder. Earlier studies have suggested that psilocybin may be a promising treatment for depression for people for whom antidepressants and therapy haven’t proven effective, but those studies focused on short-term results, while this one looked at its efficacy up to six weeks.  
Access this study